Videos | HRS | May 22, 2020
Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of...
Videos | Cardiovascular Education | May 22, 2020
Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, professor of medicine at the...
Feature | SCAI | May 21, 2020
May 21, 2020 — Here is the list of late-breaking study presentations and links to articles about each of them from the...
Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects.
News | Congenital Heart | May 21, 2020
May 21, 2020 — Two late-breaking clinical trials on trans catheter valves to treat congenital heart disease were...
Feature | HRS | May 20, 2020
May 20, 2020 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of them...
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking...
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or...
News | SCAI | May 17, 2020
May 17, 2020 – A new study shows that when compared with patients without intermediate left main coronary artery...
News | May 17, 2020
May 17, 2020 – Trial results presented today revealed a promising therapy for patients experiencing angina due to...
Icosapent Ethyl (Vascepa) significantly reduces revascularizations in statin patients based on data from the REDUCE-IT REVASC analyses, presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell
News | Pharmaceuticals | May 17, 2020
May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy....
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration.
News | Stents | May 17, 2020
May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP)...
News | SCAI | May 17, 2020
May 17, 2020 — Cindy Grines, M.D., MSCAI, a world-renowned physician credited for pioneering percutaneous coronary...
The protocol chart for the LATIN STEMI telecardiology program.
News | Telecardiology | May 15, 2020
May 15, 2020 – A groundbreaking trial recently examined the viability of telemedicine for remote guidance of a...
An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.
News | FFR Technologies | May 15, 2020
May 15, 2020 – A late-breaking study aimed to evaluate whether optical coherence tomography (OCT) can predict...
Feature | Cath Lab | May 15, 2020
May 15, 2020 – The Society for Cardiovascular Angiography and Interventions (SCAI) issued a position statement on the...
